Changes in retinal anatomy differed by drug and frequency of treatment, but did not have an
impact on vision. Data continued to show rates of death, myocardial infarction, and stroke are similar between drugs (P >0.60). The proportion of patients with serious systemic adverse events was higher with bevacizumab, with a similar cumulative risk ratio of 1.30; 39.9 percent vs. 31.7 percent. Ophthalmology, May 2012
Furnished by the American Academy of Ophthalmology and posted by John C.